{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-008203","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.378527+00:00","generated_at":"2026-05-26T04:36:47.302745+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lixte adds Northwestern's Lurie Cancer Center as second site for LB-100 + Dostarlimab trial in ovarian clear cell cancer","bullets":["Lurie Cancer Center (Northwestern University) opened as second clinical site for LB-100 plus GSK's Dostarlimab.","First patient dosed at Lurie; patient recruitment is underway. Lead investigator: Dr. Emily M. Hinchcliff.","Trial originally began in January 2024 at MD Anderson Cancer Center; lead investigator Dr. Amir Jazaeri.","Trial targets ovarian clear cell carcinoma, a disease with high unmet medical need.","LIXTE's proprietary compound LB-100 is combined with immunotherapy to enhance effectiveness."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-008203","json":"https://secwatch.observer/filing/0001493152-25-008203.json","markdown":"https://secwatch.observer/filing/0001493152-25-008203.md","text":"https://secwatch.observer/filing/0001493152-25-008203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225008203/0001493152-25-008203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225008203/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:36:47.302745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}